NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Total Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹433 Cr | ₹356 Cr | ₹287 Cr | ₹277 Cr | ₹207 Cr |
What is the latest Total Liabilities ratio of NGL FINECHEM ?
| Year | Total Liabilities |
|---|---|
| Mar2025 | ₹433 Cr |
| Mar2024 | ₹356 Cr |
| Mar2023 | ₹287 Cr |
| Mar2022 | ₹277 Cr |
| Mar2021 | ₹207 Cr |
How is Total Liabilities of NGL FINECHEM Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹433 Cr | 21.90 | |
| Mar2024 | ₹356 Cr | 23.85 | |
| Mar2023 | ₹287 Cr | 3.67 | |
| Mar2022 | ₹277 Cr | 33.53 | |
| Mar2021 | ₹207 Cr | - | |
Compare Total Liabilities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,385.0 Cr | -4% | 2.1% | 116.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹388,680.0 Cr | -2.9% | -8.9% | -3.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹168,817.0 Cr | 1.2% | 4.2% | 8.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹139,297.0 Cr | -1.7% | -3.6% | 27.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹109,828.0 Cr | 6.8% | 1.3% | 13.2% | Stock Analytics | |
| CIPLA | ₹104,588.0 Cr | 5.4% | 3.1% | -13.6% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | -4% |
2.1% |
116.6% |
| SENSEX | -2.3% |
3.3% |
-2.4% |
You may also like the below Video Courses